en · de · es · fr · pt
cjc-1295-notes.peptides4800.com › Info › Structure And Receptor Pharmacology — Research Overview

Structure And Receptor Pharmacology — Research Overview

By Editorial Desk · published 2026-05-08 · last reviewed 2026-06-30 · Info

drug affinity complex comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-06-30. Numbers and descriptions here follow the published literature rather than marketing material.

Structure And Receptor Pharmacology

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Analytical Characterization and Storage

Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.

Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.

Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.

Cjc-1295 at a glance

PropertyValueNotes
Peptide classSynthetic GHRH analogueBuilt on a 29 residue sequence
Primary targetGHRH receptor (GHRHR)Class B G protein coupled receptor
Unconjugated half lifeMinutesLimited by protease degradation
Key modificationFour residue substitutionsPositions 2, 8, 15 and 27
Common synonymModified GRF(1-29)Usually denotes the form without DAC

Background and Molecular Design

The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.

CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.

Related pages on this site

Compound Identity and Development History

CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

CJC-1295 Structure And Mechanism

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

Reference notes

=== Microanatomy === The trachea is lined with a layer of interspersed layers of column-shaped cells with cilia. The epithelium contains goblet cells, which are glandular, column-shaped cells that produce mucins, the main component of mucus. Mucus helps to moisten and protect the airways. Mucus lines the ciliated cells of the trachea to trap inhaled foreign particles that the cilia then waft upward toward the larynx and then the pharynx where it can be either swallowed into the stomach or expelled as phlegm. This self-clearing mechanism is termed mucociliary clearance. Directly beneath this mucus layer lies the submucosa layer which is composed primarily of fibrous connective tissue and connects the mucosa to the rings of hyaline cartilage beneath. The trachea is surrounded by 16 to 20 rings of hyaline cartilage; these 'rings' are incomplete and C-shaped. Two or more of the cartilages often unite, partially or completely, and they are sometimes bifurcated at their extremities. The rings are generally highly elastic but they may calcify with age.

== Interactions == The CYP3A4 inhibitors ketoconazole and verapamil strongly increase exposure to gepirone, whereas lithium, paroxetine, and warfarin have no effect on exposure to gepirone. The CYP3A4 inducer rifampin profoundly decreases exposure to gepirone.

==== Brazil ==== Just like the Argentinian marked, cider, or sidra is a very popular alcoholic beverage during the festive seasons of Christmas and New Year's in Brazil. Just like in that country, it has also been the traditional choice of the middle and lower classes for traditional sparkling for said season. Cereser, one of the most traditional cider brands in Brazil, claims on its website that "in tune with the Brazilian market" it has diversified its product range along the years from the traditional apple flavour, to other more uncommon ones elsewhere in the world, with fruity flavours ranging from peach to grapes, and including even alcohol-free ciders on its product range.

Sources: en.wikipedia.org

Reference notes

== Side effects == Side effects were reported in 37% of patients treated with arsenic trioxide. However, these effects were generally mild and resolved during treatment. Patients tolerated consolidation therapy better than induction therapy. The most common side effects include:

The material on the presynaptic and post-synaptic membranes is denser in a Type I synapse than it is in a Type II, and the Type I synaptic cleft is wider. Finally, the active zone on a Type I synapse is larger than that on a Type II synapse. The different locations of Type I and Type II synapses divide a neuron into two zones: an excitatory dendritic tree and an inhibitory cell body. From an inhibitory perspective, excitation comes in over the dendrites and spreads to the axon hillock to trigger an action potential. If the message is to be stopped, it is best stopped by applying inhibition on the cell body, close to the axon hillock, where the action potential originates. Another way to conceptualize excitatory–inhibitory interaction is to picture excitation overcoming inhibition. If the cell body is normally in an inhibited state, the only way to generate an action potential at the axon hillock is to reduce the cell body's inhibition. In this "open the gates" strategy, the excitatory message is like a racehorse ready to run down the track, but first, the inhibitory starting gate must be removed.

Following the ban on Sufi orders in the Republic of Turkey, the Bektashi community's headquarters was moved from Hacıbektaş in central Anatolia, to Tirana, Albania. In Albania, the Bektashi community declared its separation from the Sunni community and they have since perceived as a distinct Islamic sect rather than a branch of Sunni Islam. Among the most famous followers of Bektashi in Balkans during the 19th century were Ali Pasha of Yanina and Naim Frashëri.

Sources: en.wikipedia.org

Reference notes

Further reading Granger, JP; Alexander, BT; Llinas, M (2002). "Mechanisms of pressure natriuresis". Current Hypertension Reports. 4 (2): 152–9. doi:10.1007/s11906-002-0040-3. PMID 11884271. S2CID 46323264. Hall, J. E.; Mizelle, H. L.; Hildebrandt, D. A.; Brands, M. W. (1990). "Abnormal pressure natriuresis. A cause or a consequence of hypertension?". Hypertension. 15 (6_Pt_1): 547–59. doi:10.1161/01.HYP.15.6.547. PMID 1971810.

Anatomy, In Our Time. BBC Radio 4. Melvyn Bragg with guests Ruth Richardson, Andrew Cunningham and Harold Ellis. "Anatomy of the Human Body". 20th edition. 1918. Henry Gray Parsons, Frederick Gymer (1911). "Anatomy" . Encyclopædia Britannica. Vol. 1 (11th ed.). pp. 920–943. Anatomia Collection: anatomical plates 1522 to 1867 (digitized books and images) Lyman, Henry Munson. The Book of Health (1898). Science History Institute Digital Collections Archived 2 February 2019 at the Wayback Machine. Gunther von Hagens True Anatomy for New Ways of Teaching.

An adult penis with an erect length of 2.5 standard deviations (SD) below the average but otherwise formed normally is referred to in a medical context as having the micropenis condition. The condition affects 0.6% of men. Some of the identifiable causes are deficiency of pituitary growth hormone or gonadotropins, mild degrees of androgen insensitivity, a variety of genetic syndromes and variations in certain homeobox genes. Some types of micropenis can be addressed with growth hormone or testosterone treatment in early childhood. Operations are also available to increase penis size in cases of micropenis in adults.

Sources: en.wikipedia.org

Frequently asked questions

Is CJC-1295 the same as modified GRF(1-29)?

The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.

What does the acronym DAC refer to?

DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.

Does this peptide occur naturally in the body?

No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.

How is sample identity confirmed?

Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.

Network